INOVIO PHARMACEUTICALS, INC. (NASDAQ:INO) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item5.02.
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
As previously reported on the Form 8-K report Inovio
Pharmaceuticals, Inc. (the Company) filed on March9, 2017, Nancy
J. Wysenskis service on the Companys Board of Directors (the
Board) concluded effective as of the election of directors at the
Companys 2017 Annual Meeting of Stockholders held on May12, 2017.
| Item5.07. | Submission of Matters to a Vote of Security Holders. |
The Company held its 2017 Annual Meeting of Stockholders on
May12, 2017. The following are the voting results for each matter
voted upon:
Proposal 1: The election of the following nominees as directors
of the Company to serve until the Companys 2018 Annual Meeting of
Stockholders and until their successors are elected.
|
Name of Director Nominee |
Votes For | VotesWithheld | BrokerNon-Votes | |||||||||
|
Avtar S. Dhillon |
19,458,978 | 6,473,291 | 29,958,886 | |||||||||
|
J. Joseph Kim |
24,723,551 | 1,208,718 | 29,958,886 | |||||||||
|
Simon X. Benito |
24,316,572 | 1,615,697 | 29,958,886 | |||||||||
|
George W. Bickerstaff |
25,025,581 | 906,688 | 29,958,886 | |||||||||
|
ngel Cabrera |
22,491,406 | 3,440,863 | 29,958,886 | |||||||||
|
Morton Collins |
24,858,767 | 1,073,502 | 29,958,886 | |||||||||
|
Adel A.F. Mahmoud |
24,707,832 | 1,224,437 | 29,958,886 | |||||||||
|
David B. Weiner |
24,980,950 | 951,319 | 29,958,886 |
Proposal 2: The ratification of Ernst Young LLP as the Companys
independent registered public accounting firm for the year ending
December31, 2017.
| For | Against | Abstain | BrokerNon-Votes | |||||||||||
| 54,442,488 | 1,139,074 | 309,593 |
Proposal 3: The approval, by a non-binding vote, of the
compensation of the Companys named executive officers described
in the Companys proxy statement with respect to the annual
meeting.
| For | Against | Abstain | BrokerNon-Votes | |||||||||||
| 23,094,151 | 2,426,098 | 412,020 | 29,958,886 |
Proposal 4: The determination, by a non-binding vote, of three
years as the frequency with which the Company will submit to its
stockholders for approval the compensation of the Companys named
executive officers.
| One Year | Two Years | Three Years | Abstain | |||||||||||
| 12,186,089 | 1,055,461 | 12,407,447 | 283,272 |
Even though the alternative for three years received the most
votes, the Board has determined that the Company intends to
submit to its stockholders for approval, on a non-binding basis,
the compensation of the Companys named executive officers every
year.
-3-
About INOVIO PHARMACEUTICALS, INC. (NASDAQ:INO)
Inovio Pharmaceuticals, Inc. (Inovio) is a bio-pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), influenza, Ebola, Middle East respiratory syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, the Company has a pipeline of pre-clinical and clinical stage products that have generated in vivo (in the body) immune responses. INOVIO PHARMACEUTICALS, INC. (NASDAQ:INO) Recent Trading Information
INOVIO PHARMACEUTICALS, INC. (NASDAQ:INO) closed its last trading session down -0.01 at 7.34 with 1,071,583 shares trading hands.